Track Valneva SE — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Valneva SE VALN · Stock Open Valneva SE in new tab

10.85 USD
EPS
-1.54
P/B
11.02
ROE
-55.53
Beta
1.20
Target Price
12.71 USD
Loading chart...
Key Metrics
Earnings dateNov. 19, 2026
EPS-1.54
Book Value0.98
Price to Book11.02
Debt/Equity130.15
Growth
Revenue Growth-0.36%
Estimates
Forward P/E-9.95
Forward EPS-1.09
Target Mean Price12.71

DCF valuation

Model fair value for Valneva SE (VALN)
Result
Sign in to run the valuation for VALN.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 12.71 USD (low 6.85, high 18.00)
Low 6.85
Mean 12.71
High 18.00
Price 10.85
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Valneva SE Logo Valneva SE Analysis (VALN)

France Health Care Official Website Stock

Is Valneva SE a good investment? Valneva SE (VALN) is currently trading at 10.85 USD. Market analysts have a consensus price target of 12.71 USD. This suggests a potential upside from current levels.

Earnings Schedule: Valneva SE is expected to release its next earnings report on Nov. 19, 2026. The market consensus estimate for Forward EPS is -1.09.

Investor FAQ

Does Valneva SE pay a dividend?

No, it does not currently pay a dividend.

What asset class is Valneva SE?

Valneva SE is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 19, 2026. The company currently has a trailing EPS of -1.54.

Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. The company was founded in 1998 and is based in Saint-Herblain, France.

Exchange Ticker
NMS (United States) VALN
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion